Reducing Atherosclerotic Cardiovascular Disease in Patients with Type 2 Diabetes: TeleECHO Series

 

REGISTER FOR ECHO SESSION

 

Friday, July 10, 2020

9:00AM – 10:00AM ET

Please note this TeleECHO program is 9:00AM Eastern, 8:00AM, Central, 7:00AM Mountain and 6:00AM Pacific.

Program Features:

Project ECHO® is a lifelong learning and guided practice model that revolutionizes medical education and exponentially increases workforce capacity to provide best-practice specialty care and reduce health disparities. The heart of the ECHO model™ is its expansive knowledge-sharing network, led by expert teams who use multi-point videoconferencing to conduct virtual clinics with community providers. In this way, ECHO® fosters problem solving and interactive case discussion amongst doctors, nurses, and other clinicians, imparting invaluable insight to providing excellent specialty care to patients in their own communities.

The Project ECHO® format fosters dialogue and asking any questions you may have on the topic or a patient case in a HIPAA compliant manner is encouraged.

Presenting Faculty:

Silvio Inzucchi, MD
Professor of Medicine
Yale University School of Medicine
New Haven, CT

Learning Objectives

After completing the CME activity, learners should be better able to:

  • Discuss current treatment recommendations for primary and secondary prevention of atherosclerotic cardiovascular disease in patients with type 2 diabetes
  • Evaluate clinical trial data on the use of GLP-1 receptor agonists and SGLT2 inhibitors to reduce cardiovascular events in patient with type 2 diabetes
  • Review updated treatment guidelines that incorporate patient-specific factors and evidence from recent cardiovascular outcome trials to improve glycemic control and reduce cardiovascular risk in patients with type 2 diabetes

Target Audience

This educational activity is intended for primary care physicians in the United States who treat adults with type 2 diabetes.

Accreditation Statement

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 Credit(s)TM.

Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

NURSING CREDIT INFORMATION

Purpose:
This program would be beneficial for nurses involved in the care of pa­tients with type 2 diabetes mellitus.

Credits:
1.0 ANCC Contact Hour(s)

Accreditation Statement:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.

Commission On Dietetic Registration

This program has received prior approval with the Commission on Dietetic Registration for Dietitians and RDs.

ABIM Maintenance of Certification:

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact: Med Learning Group at info@medlearninggroup.com.

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/

 

REGISTER FOR ECHO SESSION

 

Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.